BibTex format
@article{Drolet:2015:10.1016/S1473-3099(14)71073-4,
author = {Drolet, M and Benard, E and Boily, M-C and Ali, H and Baandrup, L and Bauer, H and Beddows, S and Brisson, J and Brotherton, JML and Cummings, T and Donovan, B and Fairley, CK and Flagg, EW and Johnson, AM and Kahn, JA and Kavanagh, K and Kjaer, SK and Kliewer, EV and Lemieux-Mellouki, P and Markowitz, L and Mboup, A and Mesher, D and Niccolai, L and Oliphant, J and Pollock, KG and Soldan, K and Sonnenberg, P and Tabrizi, SN and Tanton, C and Brisson, M},
doi = {10.1016/S1473-3099(14)71073-4},
journal = {Lancet Infectious Diseases},
pages = {565--580},
title = {Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis},
url = {http://dx.doi.org/10.1016/S1473-3099(14)71073-4},
volume = {15},
year = {2015}
}
RIS format (EndNote, RefMan)
TY - JOUR
AB - BackgroundHuman papillomavirus (HPV) vaccination programmes were first implemented in several countries worldwide in 2007. We did a systematic review and meta-analysis to assess the population-level consequences and herd effects after female HPV vaccination programmes, to verify whether or not the high efficacy reported in randomised controlled clinical trials are materialising in real-world situations.MethodsWe searched the Medline and Embase databases (between Jan 1, 2007 and Feb 28, 2014) and conference abstracts for time-trend studies that analysed changes, between the pre-vaccination and post-vaccination periods, in the incidence or prevalence of at least one HPV-related endpoint: HPV infection, anogenital warts, and high-grade cervical lesions. We used random-effects models to derive pooled relative risk (RR) estimates. We stratified all analyses by age and sex. We did subgroup analyses by comparing studies according to vaccine type, vaccination coverage, and years since implementation of the vaccination programme. We assessed heterogeneity across studies using I 2 and χ 2 statistics and we did trends analysis to examine the dose–response association between HPV vaccination coverage and each study effect measure.FindingsWe identified 20 eligible studies, which were all undertaken in nine high-income countries and represent more than 140 million person-years of follow-up. In countries with female vaccination coverage of at least 50%, HPV type 16 and 18 infections decreased significantly between the pre-vaccination and post-vaccination periods by 68% (RR 0·32, 95% CI 0·19–0·52) and anogenital warts decreased significantly by 61% (0·39, 0·22–0·71) in girls 13–19 years of age. Significant reductions were also recorded in HPV types 31, 33, and 45 in this age group of girls (RR 0·72, 95% CI 0·54–0·96), which suggests cross-protection. Additionally, significant reductions
AU - Drolet,M
AU - Benard,E
AU - Boily,M-C
AU - Ali,H
AU - Baandrup,L
AU - Bauer,H
AU - Beddows,S
AU - Brisson,J
AU - Brotherton,JML
AU - Cummings,T
AU - Donovan,B
AU - Fairley,CK
AU - Flagg,EW
AU - Johnson,AM
AU - Kahn,JA
AU - Kavanagh,K
AU - Kjaer,SK
AU - Kliewer,EV
AU - Lemieux-Mellouki,P
AU - Markowitz,L
AU - Mboup,A
AU - Mesher,D
AU - Niccolai,L
AU - Oliphant,J
AU - Pollock,KG
AU - Soldan,K
AU - Sonnenberg,P
AU - Tabrizi,SN
AU - Tanton,C
AU - Brisson,M
DO - 10.1016/S1473-3099(14)71073-4
EP - 580
PY - 2015///
SN - 1473-3099
SP - 565
TI - Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis
T2 - Lancet Infectious Diseases
UR - http://dx.doi.org/10.1016/S1473-3099(14)71073-4
UR - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000353670600043&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR - https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(14)71073-4/fulltext#seccestitle10
VL - 15
ER -